Sumitomo Dainippon Pharma (SDP) has merged two of its US-based wholly owned subsidiaries, Tolero Pharmaceuticals and Boston Biomedical, to form Sumitomo Dainippon Pharma Oncology, the company said in a statement Wednesday.
Hiroshi Nomura, CEO of SDP, said merging the two units would help the company make oncology its core business.
